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Rationale and design of the LIBERATES 
trial: Protocol for a randomised controlled 
trial of flash glucose monitoring for 
optimisation of glycaemia in individuals 
with type 2 diabetes and recent myocardial 
infarction
Colin C Everett1 , Catherine Reynolds1, Catherine Fernandez1, 
Deborah D Stocken1, Linda D Sharples2, Thozhukat Sathyapalan3, 
Simon Heller4, Robert F Storey5 and Ramzi A Ajjan6,7
Abstract
Hyperglycaemia in individuals with type 2 diabetes (T2D) and myocardial infarction (MI) is associated with guarded clinical 
prognosis. Studies improving glucose levels in T2D following MI relied on HbA1c as the main glycaemic marker, failing 
to address potential adverse effects of hypoglycaemia and glucose variability. We describe the design of the LIBERATES 
trial that investigates the role of flash glucose monitoring in optimising glycaemic markers in high vascular risk individuals 
with T2D. This multicentre trial is designed to recruit up to 150 insulin and/or sulphonylurea-treated T2D patients, 
within 5 days of a proven MI. Individuals will be randomised 1:1 into intervention and control groups using flash glucose 
monitoring sensors and traditional self-monitoring of blood glucose, respectively. The control group will also wear a 
blinded continuous glucose monitoring sensor. The primary outcome is the difference in time spent in euglycaemia 
(defined as glucose levels between 3.9–10.0 mmol/l), comparing study groups 3 months following recruitment, assessed 
daily for 14 days and as an average. Secondary and exploratory end points include time spent in hypoglycaemia and 
hyperglycaemia, HbA1c, quality of life measures, major adverse cardiac events and cost-effectiveness of the intervention.
This study will establish the role of flash glucose monitoring in glycaemic management of individuals with T2D sustaining 
a cardiac event.
(Trial Registration: ISRCTN14974233, registered 12th June 2017)
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Introduction
Following myocardial infarction (MI), patients with dia-
betes have worse clinical outcome compared to individu-
als with normal glucose metabolism, including increased 
rate of recurrent events and higher cardiovascular and 
all-cause mortality.1–4 This adverse outcome is particu-
larly pronounced in insulin-treated patients.5 National 
and international guidelines recommend aggressive man-
agement of dyslipidaemia and hypertension in high vas-
cular risk diabetes patients, though the same guidelines 
note that a gap in the knowledge exists as to appropriate 
glycaemic management in this population.6
Given the guarded prognosis in those with hyperglycae-
mia and recent MI,7–9 a number of trials have attempted to 
investigate the effects of reducing glucose levels on clini-
cal outcome.10 However, these trials used HbA1c as the 
sole glycaemic marker, which fails to take into account 
hypoglycaemia and glucose variability, both of which are 
associated with adverse clinical outcome.11–15 
Hypoglycaemia is particularly relevant as intensive gly-
caemic control results in increased incidence of low glu-
cose levels. A meta-analysis by Boussageon et al.16 of 
randomised controlled trials (not restricted to recent MI) 
reported a pooled risk of significant hypoglycaemia in 
patients undergoing intensive glycaemic control to be over 
two-fold higher than standard control [RR 2.33 99% CI 
(1.62 to 3.36)]. Moreover, the DIGAMI-2 study10 – 
attempting to optimise glycaemic control in diabetes 
patients with myocardial infarction – unexpectedly 
observed a numerically higher mortality rate in interven-
tion groups, particularly in insulin-treated patients, sug-
gesting a detrimental effect of hypoglycaemia when 
attempting tighter glucose control. This effect was also 
seen in a systematic review and meta-analysis of 6 cohort 
studies by Goto et al.17 observing a two-fold pooled rela-
tive risk of cardiovascular disease among patients with 
hypoglycaemia [HR: 2.05 (95% CI 1.74 to 2.42)], which 
was not explained by associated comorbid illnesses.
Glycaemic studies have used HbA1c as the main gly-
caemic marker given ease of measurement and the diffi-
culties encountered in undertaking and interpreting 
self-monitoring of blood glucose (SMBG) using capillary 
testing. The main disadvantage of SMBG is the intermit-
tent nature of testing, providing limited data, and the 
opportunity for testing arising mainly when the patient 
presents feeling unwell, thus providing a biased impres-
sion of the results. Therefore, the incomplete glycaemic 
profile provided by SMBG may contribute to the uncer-
tainty surrounding cost-effectiveness of maintaining tight 
glycaemic control in this clinical situation.18,19
While traditional continuous glucose monitoring 
(CGM) provides more comprehensive glycaemic data, 
clinical use has been limited due to need for regular cali-
bration, relatively high costs and patient inconvenience 
due to bulky devices.20 However, the recently-introduced 
Freestyle Libre may address this unmet need by providing 
a convenient and comprehensive glycaemic review with 
relatively manageable costs. The Freestyle Libre consists 
of a factory-calibrated sensor that measures interstitial glu-
cose, placed on the arm with each sensor lasting for 
2 weeks. It measures glucose every 15 min and uses an 
ambulatory glucose profile (AGP) to provide an accurate, 
comprehensive method for the health care professional to 
adjust glycaemic therapy safely and effectively.
Previous randomised controlled trials have shown that 
Freestyle Libre reduces hypoglycaemic exposure both in 
type 1 and type 2 diabetes patients with the added benefit of 
reducing HbA1c in inadequately controlled type 2 diabetes 
(T2D) patients younger than 65 years.21,22 Moreover, real-
world data in over 50,000 users have shown that device use 
is associated with high frequency of glucose checks, which 
demonstrated an inverse correlation with time spent in hyper- 
or hypoglycaemia.23 A more recent study in individuals with 
T2D has shown that Freestyle Libre use is associated with a 
significant reduction in HbA1c and improved quality of life 
measures.24 However, it remains unclear whether Freestyle 
Libre offers benefits in those with associated vascular co-
morbidities, particularly following an acute event.
Therefore, we hypothesised that a modern glycaemic 
monitoring strategy would optimise glucose levels in dia-
betes patients following MI and improve quality of life in 
this population. The LIBERATES trial (improving gLu-
cose in patIents with diaBEtes following myocaRdial 
infArction: The role of a novEl glycaemic monitoring 
Strategy) has been designed to investigate the role of 
Freestyle Libre in patients with T2D following acute MI, 
which we describe in detail including study design, out-
come measures and planned statistical analysis.
Methods
List of abbreviations is provided in Table 1.
Trial design
LIBERATES is a multicentre, 2-group, 1:1 randomised, 
parallel-group, open-label Phase 2 trial investigating the 
role of flash glucose monitoring, compared with SMBG 
using capillary glucose testing, for improving glycaemic 
parameters and quality of life in a high-risk population of 
patients with T2D who have recently experienced MI.
Recruitment opened in August 2017 and the trial is 
recruiting from nine UK secondary care hospitals (Leeds, 
Sheffield, Hull, Nottingham, Birmingham, Morecambe, 
Wakefield, Reading and Stevenage). The trial is expected 
to complete follow-up in January 2020.
Objectives
The primary objective is to estimate the difference in time 
per day spent in euglycaemia, defined in this trial to be 3.9 
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to 10.0 mmol/L inclusive, between study groups at 3 months 
following a cardiac event.
Secondary objectives are to investigate differences in 
time spent in euglycaemia by 30 days post randomisation, 
times in hypoglycaemia and hyperglycaemia, HbA1c, and 
quality of life as well as reporting major cardiovascular 
events and summarising cost-effectiveness.
Trial setting
Patients with MI will be recruited during admission to sec-
ondary care UK hospitals. Recruitment will primarily be 
from cardiology wards. All patients will be recruited dur-
ing their hospital stay and within 5 days of sustaining a MI.
Eligibility criteria
Patients who satisfy all of the following inclusion criteria, 
and none of the exclusion criteria are eligible to take part 
in LIBERATES. Eligibility waivers are not permitted.
Inclusion criteria
1. Patient aged 18 years or older;
2. Pre-admission diagnosis of T2D;
3. Pre-admission treatment of hyperglycaemia with a 
sulphonylurea and/or insulin, with or without addi-
tional hypoglycaemic agents;
4. MI defined as typical symptoms of cardiac ischae-
mia associated with a typical rise in troponin levels 
using the 99th percentile threshold cut-off (patients 
with ST-elevation MI and non-ST elevation MI are 
eligible to take part);
5. Patient has provided informed consent.
Exclusion criteria
1. Solely diet-controlled T2D pre-admission;
2. Patient with active malignancy, other than local-
ised squamous cell or basal cell skin carcinoma;
3. Patient known to be pregnant, or requires dialysis;
4. Patient unable to follow study instructions or con-
sidered unsuitable for trial participation at the dis-
cretion of the treating clinician/nurse;
5. Patient previously participated in the LIBERATES 
trial.
Patients with existing pacemakers were initially excluded 
from the trial, but this criterion was relaxed following an 
amendment to the protocol, approved by the Research 
Ethics Committee (REC) in April 2019
Randomisation and blinding
Patients who are eligible and provide written informed con-
sent will be randomly allocated to either flash monitoring 
of blood glucose (intervention) or standard self-monitoring 
(control). Random allocation is provided by a central tele-
phone- and internet-based service operated, by the Clinical 
Trials Research Unit (CTRU) and only accessible by 
authorised staff, who must log-in with personalised access 
codes. Allocation sequences (stratified by centre and cur-
rent use of insulin) using Soares and Wu’s25 algorithm are 
pre-generated for each site by the trial statistician.
Patients and clinicians will not be blind to their ran-
domised allocation. In the standard care group, neither 
patients nor clinicians are able to see the Libre Pro sensor 
data nor summary reports arising. In the experimental group, 
sensor data (and summary reports) will be available to both 
patients and clinicians to act on as they see fit, either by 
life-style modifications or by changing hypoglycaemic 
medications. A simple guide for glycaemic management is 
provided to study teams but the final decision on treatment 
changes to be left at the descretion of study investigator at 
each site (suppl Appendix I). The summary reports avail-
able to clinicians in the intervention group include times in 
euglycaemia, hyper- and hypoglycaemia, so clinicians are 
not blind to the outcome measures in this group.
Interventions
Experimental – flash monitoring of glucose measurements. 
Participants randomised to the experimental group will 
monitor glucose levels by use of the flash glucose moni-
toring system.
Participants will have a Freestyle Libre sensor (Abbott 
Diabetes Care, Alameda, CA, USA) applied to the upper arm. 
The sensor is similar in design to that for the control group.
Should the sensor become detached, the participant will 
be asked to self-apply a replacement sensor, using the sup-
plied sensor applicator device. Participants will be asked 
to return all sensors used between days 0-15, 16-30 and 
76-91 at the clinic visits. Only data downloaded from the 
sensors worn between days 0-30 and 76-91 will be trans-
ferred to the CTRU for analysis.
The sensor begins recording glucose levels 60 min after 
activation, automatically records every 15 min, and holds 
8 h of data at any one time. Participants will also receive a 
handheld reader, with which they may scan the sensor to 
display current glucose levels and download the latest 8 h 
of data recorded on the sensor. Each individual is required 
to scan at least three times/day to ensure full 24-h glucose 
coverage (96 glucose readings/day), though individuals 
may scan more frequently.
The output provides a record of each observation, com-
prising date and time of the reading and recorded glucose 
level in mmol/L. Additional data available include any 
capillary glucose readings by finger-prick tests performed 
in addition to the sensor readings – the frequency of which 
will be reported – as well as medication dosages and rele-
vant dietary information, none of which is anticipated to 
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be used for analysis. Medication changes will be recorded 
at follow-up visits on case report forms (CRFs) for all par-
ticipants. The sensors have a recording range of 2.2 mmol/L 
to 27.8 mmol/L; values outside this range are set to the 
limit values. Since our outcome measures relate to time 
above, below or within standard ranges (e.g. <3.9 mmol/L 
for hypoglycaemia, >10.0 mmol/L for hyperglycaemia), 
this is not expected to impact on our analyses.
The handheld scanner used to download the sensor 
readings may also be used to measure capillary glucose 
levels by means of finger-prick testing (for example, to 
confirm reports of hypoglycaemia). Patients will be pro-
vided with a supply of glucose testing strips and will be 
asked to use only the intervention reader for such testing 
and to stop using other glucose metres during the study.
Fourteen day summaries of the time in target range, 
(3.9–10.0 mmol/L), average glucose (mmol/L), number of 
episodes and duration (minutes) of low-glucose (<3.9 and 
<3.0 mmol/l) and sensor use obtained by Freestyle Libre 
can be used to manage the treatment of participant’s blood 
glucose levels. The treating clinician may alter the patient’s 
glucose-lowering therapy at their own discretion and/or 
according to relevant guidelines based on the reported data.
Standard care – self-monitoring of blood glucose. In the 
standard care group, patients will use capillary glucose 
testing to self-monitor for 91 days post registration on a 
regular basis. To ensure standardisation of readings across 
the two group, standard care participants will be provided 
with a Freestyle glucose metre and Optium glucose testing 
strips (Abbott Diabetes Care, Alameda, CA, USA) and 
instructed to discontinue use of other glucose metres for 
the duration of the 91-day study period. Participants will 
use their own lancing device for the purpose of drawing 
blood for finger-prick testing and taking actions to control 
their blood glucose levels. Site research nurses will update 
knowledge on glucose testing and will familiarise patients 
with the new glucose metre. At follow-up visits, data from 
the glucose metre will be downloaded and used by the 
attending team to adjust glycaemic therapy in line with 
local management policies.
For the purposes of endpoint data collection during the 
time periods 0-15 days, 16-30 days and 76-91 days, standard 
care group participants will also have a Freestyle Libre Pro 
(Abbott Diabetes Care, Alameda, CA, USA) sensor applied 
to their skin. Freestyle Libre pro sensor is identical to the 
sensor used in the interventional arm of the study except for 
having glucose data blinded to patients, health care profes-
sionals and study investigators. Should the sensor become 
detached prior to the end of the recording period, partici-
pants will visit their recruiting hospital to have a new sensor 
attached, to ensure sufficient data records.
The sensor begins recording glucose levels 60 min after 
activation and automatically records glucose every 15 min 
(up to 96 readings per day) for up to 14 days. At day 15, 30 
and 91 visits, the research team will remove the sensor and 
download the results using the Freestyle Libre Pro reader. 
Neither participant nor treating clinician/nurse will have 
access to this data at any time, so these data will not influ-
ence treatment recommendations.
The output data for analysis is in the same format as 
for the intervention group, with the same recording 
ranges.
No summary report will be generated for the patients in 
the standard care group. The treating clinicians will adjust 
the patient’s glycaemic therapy based on the results of con-
ventional clinical follow-up and any self-monitoring blood 
glucose results the patient may provide.
Outcome measures
Primary outcome measure. Glucose control, measured by 
the time per day that glucose is in the range 3.9–
10.0 mmol/L inclusive,26 measured between days 76–91.
Secondary outcome measures
•• Glucose control, measured by the time in range 
(3.9–10.0 mmol/L inclusive) per day, between days 
15 and 30;
•• Glucose control, measured by the time per day in 
hyperglycaemia (glucose > 10.0 mmol/L) between 
days 15 and 30, and days 76 and 91;
•• Glucose control, measured by the time per day in 
hypoglycaemia (glucose < 3.9 mmol/L) between 
days 15 and 30, and days 76 and 91;
•• HbA1c (mmol/mol) value at day 91;
•• Weight (Kg) value at day 91;
•• Blood Pressure (Systolic and Diastolic) values at 
day 91;
•• Health and treatment-related quality of life meas-
ured by EQ-5D-5L utility score, Diabetes Treatment 
Satisfaction Scale score and Audit of Diabetes 
Dependent Quality of Life questionnaire domain 
and overall scores at day 91;
•• Safety, measured as incidence of mild, moderate 
and severe pre-specified trial specific adverse 
events reported from days 0 to 91;
•• Cost-effectiveness;
Exploratory outcome measures
•• Glucose control, measured by the time per day in 
“significant hypoglycaemia” (glucose < 3.0 mmol/L) 
between days 76 and 91;
•• Glucose control, measured by the time per day in 
“extreme hypoglycaemia” (glucose < 2.5 mmol/L) 
between days 76 and 91;
•• Major adverse cardiovascular events (MACE) 
within maximum 12 months;
•• Severe hypoglycaemia (defined as requiring 3rd 
party assistance with recovery) in months 1 to 3 and 
in months 4 to 12;
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•• Diabetes-related hospitalisations within maximum 
12 months;
•• All-cause mortality within maximum 12 months;
•• Changes in care, measured by changes in diabetes 
and other cardiac medication usage within 91 days.
The MACE endpoint is defined as death due to cardiac 
cause or hospitalisation for one of the following: acute 
coronary syndrome (including MI and unstable angina); 
heart failure; unscheduled revascularisation (by percutane-
ous coronary intervention or coronary artery bypass graft); 
Figure 1. Summary of assessments, and timing of outcome assessments.
1The final follow-up visit will take place 12 months post randomisation for patients randomised before 31st January 2019, and at visit closest to 31st 
January 2020 for those randomised later.
2Libre Pro sensor data to be downloaded after the participant has left the clinic and must NOT be viewed by the treating clinician/nurse.
SMBG: self-monitoring of blood glucose.
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arrhythmia; cerebrovascular event (including thrombotic 
or haemorrhagic stroke and transient ischaemic attack).
Data collection
Figure 1 illustrates the data collected at the specific time 
points in the LIBERATES study.
Clinical data will be recorded at sites on paper CRFs, 
copies of which will be retained at site while originals will 
be sent to the CTRU. To ensure patient confidentiality, 
CRFs will only record the sequential patient trial identifier, 
and the patient date of birth and initials for verification. 
Consent forms will record NHS Number and full name and 
contact details for each patient. Data will be entered onto a 
database (MACRO, Infermed), which will have specified 
a number of validation checks to automatically identify 
certain erroneous data items. Reported discrepancies will 
be returned to sites for data clarification.
Endpoint data relating to glucose control automatically 
collected by the glucose sensors will be downloaded at the 
hospital. Raw glucose levels at each date/time point will 
be transferred to the CTRU by an encrypted file transfer 
service and stored electronically in a location accessible 
only to the trial data manager and statistician. Transferred 
data files will identify the patient only by referring to the 
unique trial ID, patient initials, and date of birth, and will 
identify the study visit number and visit date.
At the day 15, 30, 76 and 91 follow-up visits, partici-
pants will be prompted to report the occurrence and fre-
quency of any expected safety events relating to diabetes or 
to the glucose sensor. Any related and unexpected serious 
adverse events (RUSAEs) will be reported separately and 
are subject to expedited review: RUSAEs will be reported 
to the CTRU within 24 h of the site becoming aware of the 
event. The event will be reviewed by the Chief Investigator 
(CI) and will be reported to the sponsor within 1 day of 
CTRU becoming aware, and reported by the CTRU to the 
main Research Ethics Committee within 15 days.
Patients recruited prior to 31st January 2019 will have 
their final follow-up visit 1 year after randomisation. Those 
recruited between 1st January and end of recruitment will 
have their final follow-up visit as close as possible to 31st 
January 2020. At the final follow-up time point, the recruit-
ing hospital will contact the patient (and/or look at the 
patient’s medical notes) to obtain information on diabetic 
complications, severe hypoglycaemia, mortality, diabetes-
related hospitalisations, and hospitalisation for acute coro-
nary syndrome (including MI and unstable angina), heart 
failure, unscheduled revascularisation, arrhythmia or cer-
ebrovascular events.
Participants who cease using the sensors will be fol-
lowed up according to the trial schedule. Participants will 
have the option to withdraw from the follow-up period for 
any reason and will have the option to permit staff to 
access medical records to identify long-term events.
Statistical considerations
Sample size. The sample size of 150 patients is based on a 
realistic recruitment target and according to a Bayesian 
decision rule for the primary outcome. Our decision rule 
would be that progression to an international definitive 
trial is indicated if the observed posterior probability of a 
positive treatment effect is 80% or greater. A simulation-
based approach was used to estimate posterior probability 
of a positive difference in time in euglycaemia (in favour 
of the Freestyle Libre). The following assumptions were 
made, based on previous published data,22 as well as 
unpublished data from 14 patients each providing meas-
urements of time in euglycaemia for 7 days:
•• mean time per day in euglycaemia of 13.3 h in the 
control group;
•• mean time per day in euglycaemia of 14.8 h in the 
intervention group (effect of 1.5 h);
•• between-patient variance of 32.90;
•• residual (within-patient) variance of 10.97;
•• intra-class correlation of 0.75;
•• minimum of 9 days complete data per patient, with 
days 10-14 each having an independent 20% chance 
of being unobserved.
Table 1. List of abbreviations.
ADDQoL Audit of Diabetes Dependent Quality of Life
AGP Ambulatory Glucose Profile
CI Confidence Interval
CGM Continuous Glucose Monitoring
CRF Case Report Form
CTRU Clinical Trials Research Unit
DTSQs Diabetes Treatment Satisfaction Questionnaire 
(status)
EASD European Association for the Study of Diabetes
EQ-5D-5L Euroqol 5-dimension health questionnaire
ESC European Society of Cardiology
HbA1c Glycated Haemoglobin
HRA Health Research Authority
MACE Major Adverse Cardiovascular Events
MI Myocardial Infarction
NHS National Health Service
NICE National Institute for health and Care Excellence
NIHR National Institute for Health Research
NSTEMI Non-ST Elevation Myocardial Infarction
PIL Patient Information Leaflet
PIN Personal Identification Number
QALY Quality-Adjusted Life Year
REC Research Ethics Committee
RfPB Research for Patient Benefit
RUSAE Related and Unexpected Serious Adverse Event
SMBG Self-Monitoring of Blood Glucose
STEMI ST Elevation Myocardial Infarction
T2D Type 2 Diabetes
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Based on 1000 simulations, the expected posterior proba-
bility of the difference in the time in euglycaemia (defined 
in study participants as glucose levels between 3.9-10.0 
mmol/l) between the groups being greater than zero (condi-
tional on 1.5 h being both the observed and true difference) 
would be 0.958 (90% interval 0.946–0.97). In the same sce-
nario, if 20% of participants are lost to follow-up, then the 
expected posterior probability would be 0.939 (0.921, 
0.957). The posterior probabilities calculated assumed an 
uninformative prior distribution. Table 2 summarises the 
expected standard errors from the simulations, and the 
mean (90% percentile interval) of the posterior probabili-
ties for a range of sample sizes and potential observed inter-
vention effects. In summary, with 150 patients, there is a 
high chance (>90%) of concluding a treatment benefit if 
the true difference between the groups is at least 1.5 h.
Analysis methods. Prior to final analysis, a full Statistical 
Analysis Plan will define analysis populations, outcome 
measure derivations, procedures for imputing missing data 
(and/or conducting analysis in the presence of missing data), 
and specific analyses for each endpoint, including covariate 
adjustments, sensitivity analyses and any further explora-
tory analyses. The CI will approve the final version.
Primary analyses will be on an intention-to-treat (ITT) 
basis, in which all patients are included in analyses in the 
group to which they are assigned at randomisation, regard-
less of study completion or protocol adherence. Sensitivity 
analyses will consider a per-protocol (PP) analysis (for 
which a minimum degree of compliance will be agreed by 
the Trial Management Group) and an appropriate randomi-
sation-respecting efficacy analysis (for example, Principal 
Stratification).
The primary outcome measure will be analysed and 
interpreted within the Bayesian framework, estimating 
and reporting the posterior probability of a positive effect. 
If this posterior probability is 0.8 or more, then this would 
indicate that moving to a definitive trial is recommended. 
The primary analysis will use proper but uninformative 
prior distributions for all parameters in the model. 
Sensitivity analysis will consider more informative priors, 
based on previous published data, as sensitivity 
analyses.27,28 The outcome measure itself will be the time 
in each individual 24-h period that the patient’s glucose 
spends in the range [3.9, 10.0 mmol/L], thus each patient 
will have multiple readings within the 76 to 91 day range. 
These will be analysed using a hierarchical longitudinal 
repeated measures model, comprising random intercepts 
for patients and centres, and random slopes for time, as 
well as fixed effects for intervention arm, insulin use, 
time, time-by- intervention interaction and day 0 time in 
range. We will initially assume a linear effect of time, but 
alternative patterns of change will be considered when 
data are available. The Bayesian posterior probability of 
positive intervention effect will be reported, when using 
prior distributions for main effects and covariances that 
are proper and non-informative. An additional analysis 
will account for possible moderating effect of baseline 
insulin use on the outcome measure, by including a fixed 
effect for the interaction between baseline insulin use and 
the intervention arm. Finally, for an ancillary analysis, we 
will obtain a single mean average time per day in normal 
range for each patient, and fit a conventional linear regres-
sion model, adjusting for fixed effects of insulin use, 
mean baseline glucose level and random intercept effects 
for randomising centre. This analysis will allow compari-
son between our results and other published trials using 
such analysis approaches.
Table 3 lists the planned analysis approach for the sec-
ondary and exploratory outcome measures. In general, 
analyses will take the form of regression models that adjust 
for the stratification factors, reported as estimated effect 
sizes with 95% confidence intervals. Analyses of “time per 
day” with glucose in a given range will be derived and 
analysed analogously to the primary outcome measure, 
though not within the Bayesian framework.
To allow for the possibility of sensor data not being 
recorded or not available, missing data will be primarily 
dealt with under the “missing at random” assumption.29 
Analyses will either use multiple imputation to produce a 
number of completed datasets – analysed individually 
before combining resulting estimates – or will use maxi-
mum likelihood analysis of mixed models with random 
patient effects to meet this assumption. Sensitivity 
Table 2. Results of simulations to estimate standard errors from primary analysis models and expected posterior probabilities of 
concluding a positive treatment effect. Mean probabilities are given with 90% intervals for the posterior probabilities observed in 
the simulations. d̂ = observed (and true) treatment effect.
Total sample size 
(n per group)
Expected 
standard error
Pr (d>0|data)* if d̂ =1.5 Pr (d>0|data) if d̂ =1.0 Pr (d>0|data) if d̂ =0.5
60 (30) 1.353 0.867 (0.837, 0.897) 0.771 (0.744, 0.8) 0.645 (0.628, 0.663)
80 (40) 1.175 0.899 (0.874, 0.924) 0.803 (0.777, 0.831) 0.665 (0.649, 0.684)
100 (50) 1.057 0.922 (0.903, 0.942) 0.828 (0.807, 0.853) 0.682 (0.667, 0.7)
120 (60) 0.967 0.939 (0.921, 0.957) 0.85 (0.827, 0.874) 0.698 (0.681, 0.717)
140 (70) 0.896 0.953 (0.938, 0.967) 0.868 (0.848, 0.89) 0.712 (0.696, 0.73)
150 (75) 0.867 0.958 (0.946, 0.97) 0.876 (0.858, 0.895) 0.718 (0.704, 0.735)
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analyses will consider the effect of departures from the 
“missing at random” assumption.
Analyses of secondary outcome measures that may be 
affected by the 1-year follow-up being truncated will either 
be assessed by appropriate time-to-event analysis methods 
or by regression methods including offset terms for the 
duration of follow-up.
Economic evaluation methods. The Cost-Effectiveness 
analysis will be performed according to the reference 
case guidance for technology appraisals set out by 
NICE.30
At 91 days, a cost-consequences analysis will be per-
formed in order to contrast the difference in health care 
cost with the difference in EQ-5D-5L scores (converted to 
Quality-Adjusted Life Years (QALYs)), diabetes treatment 
satisfaction levels (measured using DTSQs) and time spent 
in euglycaemia between the intervention and standard care 
and control groups.
Trial governance and oversight
Ethical approval was obtained from the Yorkshire and 
Humber Leeds East REC on 28th June 2017. (REC reference 
Table 3. Summary of planned statistical analysis approaches for the secondary and exploratory outcome measures.
Outcome measure Brief analysis plan
Secondary
Time per day in euglycaemia [3.9, 10.0 mmol/L] (at days 16–30) Multi-level longitudinal mixed effects linear regression 
model, adjusted for random centre intercept effects*, 
fixed effects of insulin use, baseline glucose, time, time-
by-treatment interaction and day 0 time in euglycaemia, 
random effects for patient and patient by time.
Time per day in hyperglycaemia (>10.0 mmol/L) (at days 76–91 and 
days 16–30)
Time per day in hypoglycaemia <3.9 mmol/L) (at days 76–91 and 
days 16–30)
Ancillary analysis: linear regression model, adjusted for 
fixed/random centre effects*, fixed effects of insulin use 
and baseline glucose level.
HbA1c Linear regression, adjusted for fixed / random centre 
effects*, fixed effects of insulin use and baseline value.Weight
Blood Pressure
DTSQs scores
EQ5D-5L utility score
ADDQol scores
(all at day 91)
Exploratory
Time per day in significant hypoglycaemia [<3.0 mmol/L) (at days 
76–91 and days 16–30)
Multi-level linear regression model, adjusted for random 
centre effects*, fixed effects of insulin use, baseline 
glucose, time, time-by-treatment interaction, random 
effects for patient and patient by time.
Time per day in extreme hyperglycaemia [< 2.5 mmol/L) (at days 
76–91 and days 16–30)
Ancillary analysis: linear regression model, adjusted for 
fixed / random centre effects*, fixed effects of insulin 
use and baseline glucose level.
Proportions of patients For all except deaths: Poisson regression, including 
offset term for duration of follow-up, adjusted for 
fixed effects of insulin use and random centre effects. 
Unadjusted differences in proportions between groups.
+ experiencing severe hypoglycaemia that requires third party 
assistance (in months 1–3 and 4–12)
+ experiencing MACE within
maximum 12 months
hospitalised for diabetes-related causes within maximum 12 months
+ deceased within maximum 12 months (all causes) For deaths: Summary statistics by centre, insulin status 
and group. Unadjusted differences in proportions 
deceased in the two groups.
Time until first Kaplan-Meier estimates of proportions event-free, 
stratified (by centre and insulin use), log-rank test. 
Time-to-event regression model (e.g. Cox proportional 
hazards, accelerated failure) adjusted for fixed effect of 
insulin use and random centre effects*.
+ MACE
+ Diabetes-related hospitalisation
+ Death (all causes)
Use of diabetic and other cardiovascular medications Summary statistics by group
Adverse Events
*Centre will be fitted as a random (intercept) effect in the first instance. If centre sizes are too small to permit this and/or result in non-positive 
variance estimates, we will not adjust for randomising centre. Small centres will not be combined to form larger “pseudo-centres” to improve model fit.
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17/YH/0163) Approval from the Health Research Authority 
(HRA) was received on 4th July 2017. The most recent 
amendment to the protocol was approved in April 2019.
The sponsor for the trial is the University of Leeds. 
Given the low risk of the intervention, oversight of the 
study is provided by a single Trial Safety and Oversight 
committee (TSOC) combining the roles of a Data 
Monitoring and Ethics Committee and a Trial Steering 
Committee. The TSOC comprises an independent statisti-
cian, two independent clinicians and an independent 
patient representative. No formal interim analyses of 
safety or efficacy will be performed, hence there are no 
rules or guidelines for early trial termination.
After completion of final analysis, the final trial dataset 
will be property of the trial team and held at CTRU, 
University of Leeds. The trial team has agreed for a copy 
of the final clinical study report to be shared with funders 
(Abbott and NIHR) as part of the contractual agreement, in 
addition to access to manuscripts and abstracts for publica-
tion or dissemination.
No release of trial data will take place until after publi-
cation of the main trial results. Access to the trial dataset 
for bona fide research purposes will require a signed 
legally-binding contract to ensure the data security and 
confidentiality of participants and defining particularly the 
data items requested and planned analyses. Participants 
will only be included in shared datasets if they consented. 
Data will be anonymised prior to any data transfer.
Discussion
We describe the scientific rationale and design of the 
LIBERATES trial. This trial will recruit T2D patients with 
recent MI to test whether the use of Freestyle Libre leads to 
better glycaemic control compared with standard care con-
sisting of self-monitoring of capillary glucose measure-
ments. This trial aims to establish differences in glucose 
parameters between two study groups in a relatively limited 
number of patients, akin to other CGM studies. Data from 
the work will establish the feasibility of a larger scale study 
investigating hard clinical outcomes in individuals with 
T2D and recent MI, including MACE and mortality.
Glycated haemoglobin is a convenient outcome meas-
ure of average plasma glucose levels over a 3-month 
period. However, it does not provide an assessment of 
hypoglycaemia, nor variability in glucose levels, both of 
which are associated with adverse outcomes. CGM per-
mits such swings to be detected, providing a more compre-
hensive assessment of glycaemia.
Previous randomised controlled trials with Freestyle 
Libre in T2D are limited to two studies. The REPLACE 
study (NCT0208218422) recruited 224 inadequately con-
trolled, insulin-treated T2D patients, having HbA1c 
between 7.5% and 12% (58–108 mmol/mol). Individuals 
were randomised on 2:1 basis to intervention using flash 
glucose monitoring and standard control group employing 
SMBG for glucose measurements. Flash glucose monitor-
ing did not show improvement in HbA1c, although a pre-
specified subgroup analysis of patients younger than 
65 years showed significant reduction in HbA1c by 
5 mmol/mol in the Libre group compared with standard 
care (after adjustment for baseline). A more recent study 
on 101 insulin-treated individuals with T2D has shown a 
significant reduction in HbA1c and improvement in qual-
ity of life measures in the group managed with Freestyle 
Libre compared with SMBG.24
The LIBERATES trial is novel in that it targets a higher 
vascular risk population with T2D patients. This is a par-
ticularly difficult group due to patient concerns following 
a life-threatening event, the need to undergo various pro-
cedures and start of new therapies. Therefore, glycaemia 
often becomes of secondary importance despite the docu-
mented association between high glucose levels and 
adverse clinical outcome.
The planned analysis of LIBERATES is also novel in 
that continuous glucose traces will not be averaged to 
create a single value per patient: rather, the trace will be 
partitioned into individual daily readings, to be analysed 
as a repeated measures longitudinal analysis. By doing 
so, the information in the data can be maximised with 
changes in glucose control modelled over time, and the 
correlation between measurements made on the same 
patient taken into account. However, traditional analysis 
of the aggregated data will also be undertaken to enable 
comparison with published results from RCTs and obser-
vational studies.
The LIBERATES trial will provide valuable informa-
tion on the use of Freestyle Libre in T2D patients with 
recent MI who are at risk of hypoglycaemia. It will clarify 
the role of Freestyle Libre in improving glycaemic param-
eters and quality of life in this highly stressed group. In 
particular, multiple glycaemic markers will be studied, 
thus providing a comprehensive assessment of glycaemia 
to aid the clinical management of these patients. Also, it 
will provide preliminary data for a large multinational 
clinical outcome study investigating the use of this device 
to improve short and medium-term clinical outcome in 
diabetes patients post MI.
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